SHANGHAI PIONEER HOLDING LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.88 HKD | 0.00% |
|
-2.08% | +2.73% |
| 04-24 | Shanghai Pioneer to Hire New Auditor | MT |
| 03-26 | Shanghai Pioneer Holding's 2023 Profit Falls as Revenue Stays Flat | MT |
| Sales 2021 | 1.43B 198M 1.55B 15.86B | Sales 2022 | 1.56B 215M 1.68B 17.2B | Capitalization | 2.36B 325M 2.54B 26.03B |
|---|---|---|---|---|---|
| Net income 2021 | 143M 19.74M 154M 1.58B | Net income 2022 | 235M 32.43M 254M 2.6B | EV / Sales 2021 | 0.88 x |
| Net cash position 2021 | 388M 53.55M 419M 4.29B | Net cash position 2022 | 251M 34.7M 272M 2.78B | EV / Sales 2022 | 1.35 x |
| P/E ratio 2021 |
11.5
x | P/E ratio 2022 |
9.97
x | Employees | 345 |
| Yield 2021 |
7.28% | Yield 2022 |
3.05% | Free-Float | 32.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -2.08% | ||
| 1 month | +17.50% | ||
| 3 months | +6.82% | ||
| 6 months | -3.09% | ||
| Current year | +2.73% |
1 week
1.75
1.92
1 month
1.711.95
Current year
1.311.95
1 year
1.312.73
3 years
0.932.95
5 years
0.512.95
10 years
0.517.79
| Managers | Title | Age | Since |
|---|---|---|---|
Xin Zhou Li
FOU | Founder | 60 | 30/06/96 |
Yi Xue
DFI | Director of Finance/CFO | 49 | 31/01/15 |
Yue Wen Yang
COO | Chief Operating Officer | 36 | 31/08/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xin Zhou Li
FOU | Founder | 60 | 30/06/96 |
Chan Shu Lai
BRD | Director/Board Member | 77 | 15/10/13 |
Hong Zhang
BRD | Director/Board Member | 65 | 31/12/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.88 | 0.00% | 0 |
| 25/04/24 | 1.88 | -2.59% | 0 |
| 24/04/24 | 1.93 | +1.58% | 2,000 |
| 23/04/24 | 1.9 | +5.56% | 311,000 |
| 22/04/24 | 1.8 | -6.25% | 10,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Shanghai Pioneer Holding Ltd, formerly China Pioneer Pharma Holdings Ltd, is a China-based investment holding company mainly engaged in the marketing, promotion and sales of pharmaceutical products, medical devices and personal protective equipment. The Company operates mainly through three segments. The Products Sold via the Provision of Channel Management Services segment is principally engaged in the sales of the Company's ophthalmic pharmaceutical products to customers through pipeline management arrangements. The Products Sold via the Provision of Comprehensive Marketing, Promotion and Channel Management Services segment is principally engaged in the sale of all of the Company's pharmaceutical products and medical devices to customers through comprehensive marketing, promotion and channel management arrangements. The Sales of Personal Protective Materials segment is mainly engaged in the sales of personal protective materials include masks, protective gloves and protective suits.
Sector
Pharmaceuticals
Calendar
29/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.73% | 283M | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -3.38% | 3.93B | |
| -2.61% | 3.86B |
- Stock Market
- Equities
- 1345 Stock
